[PDF] Top 20 Original Article Does the age affect the efficacy of anti-VEGF agents in advanced non-small-cell lung cancer? A meta-analysis
Has 10000 "Original Article Does the age affect the efficacy of anti-VEGF agents in advanced non-small-cell lung cancer? A meta-analysis" found on our website. Below are the top 20 most common "Original Article Does the age affect the efficacy of anti-VEGF agents in advanced non-small-cell lung cancer? A meta-analysis".
Original Article Does the age affect the efficacy of anti-VEGF agents in advanced non-small-cell lung cancer? A meta-analysis
... containing anti- VEGF agents has substantial improvements for PFS outcomes in elderly patients when com- pared to controls ...of anti-VEGF agents to treatment therapies could ... See full document
7
Original Article Efficacy and safety of non-platinum based doublets chemotherapy compared with platinum-based doublets chemotherapy in advanced non-small-cell lung cancer (NSCLC): a meta-analysis
... ising efficacy and low ...the meta-analysis and the efficacy and safety of third-generation agents doublets chemothera- py and platinum plus third-generation agent doublets chemotherapy ... See full document
12
Original Article Hypertension does not influence response to EGFR targeted therapy in patients with advanced non-small-cell lung cancer
... the efficacy of targeted therapy and such special patients is necessary and impor- ...too small. Therefore, further study is needed to evaluate the efficacy of EGFR-TKIs in the treatment of brain ... See full document
7
Efficacy of targeted agents in the treatment of elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis
... as anti-EGFR monoclonal antibodies (cetuximab and necitumumab), immune modulator (thalidomide), and small multikinase inhibitor targeting VEGF receptor/platelet- derived growth factor ... See full document
7
Original Article The efficacy and safety of lcotinib in patients with advanced non-small cell lung cancer: compare with gefitinib
... recent analysis, about 35% of patients in East Asia were diagnosed as non- small cell lung cancer with EGFR mutations ...locally advanced or metastatic ...too ... See full document
7
Original Article Effects of ginsenoside Rg3 combined with 125 I seeds on serum TGF-α, TGF-β1, and VEGF in patients with medium and advanced non-small cell lung cancer
... with anti-tumor effects ...tumor cell apoptosis, and inhibit invasion and metastasis of cancer ...can affect the cycle of lung tumor cells and slow down the prolifera- tion of tumor ... See full document
7
Original Article Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy
... platinum age- nts in advanced NSCLC patients ...motherapeutic agents and modulate drug ...previous meta- analysis regarding on the association between GS- TP1 A313G polymorphism and ... See full document
7
Original Article The efficacy and toxicity of anti-VEGFR agents in the treatment of advanced colorectal cancer: a meta-analysis of randomized controlled trials
... this analysis. Firstly, our study is a meta-analysis of published data, and we could not get individual patient data, which might prevents us to investigate the treatment efficacy based on ... See full document
7
Original Article Efficacy and safety of Endostar (recombinant human endostatin hormone) combined with docetaxel as second-or third-line therapy for patients with non-small-cell lung cancer
... good anti-tumor efficacy in solid tumors with well-tolerated tox- icity ...ly advanced NSCLC patients was feasible and showed promising survival and local control rates ...A ... See full document
10
Original Article Comparative survival analysis of the treatment options for TKI resistant advanced non-small cell lung cancer (NSCLC) patients: a meta-analysis
... for non-small cell lung cancer ...a meta-analysis of efficacy and survival outcomes of various treatment options for NSCLC patients with acquired resistance to ... See full document
15
Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review
... with anti-VEGF agents in advanced NSCLC remains ...a meta-analysis of published trials to investigate the risk of ATEs and VTEs associated with the use of anti-VEGF ... See full document
10
Original Article Clinical efficacy of bevacizumab combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer
... against VEGF, bevacizumab can in- hibit the binding of VEGF to its receptor which inhibits tumor angiogenesis while promoting degeneration of tumor new vessels and nor- malization of survival vessels, ... See full document
9
Original Article Association of GSTs gene polymorphisms with treatment outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy
... Against Cancer (UICC)/ American Joint Committee on Cancer ...with advanced NSCLC were followed up until the date of October ...with advanced NSCLC signed written informed consents before ... See full document
7
Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib
... Comprehensive Cancer Network guidelines recommended new strategies for patients resistant to crizotinib according to response evaluation criteria in solid tumors ...An analysis of 194 patients from PROFILE ... See full document
9
Original Article High glasgow prognostic score associates with a poor survival in Chinese advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy
... of Cancer Center, First Affiliated Hospital, Jilin University, Chang- chun, Jilin, ...the Cancer Medicine Center, Cancer Center, First Affiliated Hospital, Jilin University, Changchun, Jilin, ... See full document
7
New targeted treatments for non-small-cell lung cancer – role of nivolumab
... A Phase I trial with expansion cohorts was conducted between 2008 and 2012 (Figure 3 and Table 2), aiming to assess activity and safety of biweekly nivolumab at a dose of 1–10 mg/kg. A total of 296 heavily pretreated ... See full document
15
<em>EGFR</em> mutations as a prognostic and predictive marker in non-small-cell lung cancer
... As we can see from the results of the abovementioned studies, it has not been established whether EGFR mutations could predict the outcomes in NSCLC patients treated with cytotoxic chemotherapy. Regarding the results ... See full document
17
Systematic review and meta analysis of Endostar (rh endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non small cell lung cancer
... molecule [6]. The direct target of endostatin is the new ca- pillary endothelial cells around the tumor. Endostar (YH- 16), a novel recombinant human endostatin expressed and purified in Escherichia coli, was approved by ... See full document
12
Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
... of non-small-cell lung cancer (NSCLC) patients implicates the oncogenic nature of activated ALK pathways in this subset of metastatic ... See full document
8
Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis
... the efficacy and safety profile of adding COX-2 inhibitors to chemotherapy alone; 2) only includ- ing patients with cytologically or histologically confirmed NSCLC stage IIIB or IV; 3) full paper in English ... See full document
10
Related subjects